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A lEDlC/SBD Di\Y FOJU.i FOR

LOCl~.L ?IIEi.U~.PY

IH DWL·;CTED BURHS

Abstract of

Diss<~rta tion

Local burn therapy usually includes the application of medicated
oint ments and dressings in order to lllinim.ize and eradicate infectioH .
As this approach to l ocal therapy may present probleG".S r egardine
application and r ewovLll techniques, i t vms the purpose of t his study
to fomulate a topical dosage form that L'!a.Y be apphed to denuded
c..reas of the skin ''i thout i nunction. Using the cor!ccpt of topical
films, a dosar;e for m "ras for!!!ulated that is highl y water soluble ,
f l exible , and edhercnt to both denuded and illt<.:ct "-rees of the :::ldn.
In order to develop a dosage form u i th these cha r acteristics ,
a v ehicle consi sting of t-iiranol 2t·1CA Hodified, sorbitol, dextrcn ,
c:.nd wate r \'.'as formulated . 'I'his hydrO})hiJic, aerated film \WS
compounded und evulua t ed by the use of :i.n vi_trQ. and. il]_~~L.9. 11ethods .
In addi titm , ::;tability tests v:ere r:erformed to immre c.deq_uate
shelf l ife .
'l'hc rtJl ease of therapentic agents irL vi tr:g_ froo dry foam formulations vlas cor~pared Ni th t.~.1at of co:r.r espor.ding ointl:le:lt bases ,
utilizing a modified a ga1· diffusion test . Using Fseadol:lonas seruginosa
as the tent bacteria , these t est s shO\ofed t hat silver ni tra.te and
s ilver sulfadiazine produce sicrnifi cantly lorger zor.es 0f inhibition
when used tiS t he cry foam r a ther than as an oint n:ent . Ho\o~ever ,
me.fenide a.cetate and gent e..micin sulfate produced equivalent r elec.s e
rates f r om both t he dry foal:l and ointment .
·I n vivo. studies demons trated tha t incidence of infection '.lS:i.ng
the burned , infected guinea pig was statistical ly equi valent when
rnafenide acetate was applied a s either the dry foam or the commercially
available ointment . A therape utic r er,i roe using silver sulfadiazin~
dry foam produced s ignificantly better results than vrith the
c orres ponding ointment, i f therapy was initiated one-hal f hour after
inoculating the animals . However, by delaying the r apy for 72 h ours,
incidence of infection after trea t ment v:i th ei thcr preparation v:e.s
without s i gnificant difference.
As t he dry f oa@ formulationo deoo1~trateu not less than equivalent
efficacy when compar ed to ointment bu.ses in curr ent usage , it appears
t hat u medicated dry foru.1 11ill be of va l ue as a vehicle for topical
use . By clicinating t he need to spread the dosage forw. onto skin
lesions I:l~~ual ly , the dry foaL1 may prove to be of value i n trea t ing
the seriously burned patient. Further , by the use of a h i ghly water
soluble t opical dosage fo r m, r err:ovl:il may be accompl ished v~i thout injury
to denuded areas .
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INTRODUCTION
The massive burn produces a complexity of serious
problems which must be handled in a comprehensive manner.
The intensit;y of pa in is pe rhaps obvious to any who have
had even minor thermal injuries.

However, fluid a nd elec-

trolyte shifts and shock response may po se a:n immediate
life threatening condition in the massively burned patient.
In a ddition to these, invariably there is maj or disrupt ion
in the anatomy and anatomical function of the skin.

Dis-

ruption of normal skin structure opens avenues for loss of
fluid and entry of microorganisms into the body • . Invasi on
of burn vlOunds by bacteJ:ia may present a potentially life
threatening hazard to the patient, should their e stabli s h-·
ment result in septicemia and abnormal wound healing.
is primarily toward these problems that topical theraj:·Y Dust
be considered as a major component of the therapeutic ::::"es i men employed in the total management of the patient.

I t is

the intention of this study to address itself to considera tions of methods and materials employed in topical anti·bacteria l therF.lpy for the severely burned patient.
Histor:y of Topical Burn Tber2:.J2;Y.
As interest in therapy for those injuries caus ed by
heat dat es back to the early days of mankind, severa l
authors have r eviewed the hi s tory of topical burn therapy (1,2) ..

2

Hippocrates suggested the f'ollovJing treatment:

11

Having

melted old swine seam and mixed it with resin and bitumen,
and having spread it on a piece of cloth and v1armed it at
the fire, apply the bandage .. 11

By the seventh century, A.D.,

local therapy consisted of the application of various
emollient preparations..

Oleaginous, emollient substances

were also recommended by Pare in the sixteenth century for
topical treatment of the burned patient.

During the nine-

teenth century, Ballingal, a British surgeon, recognized
that mortality following a severe burn was due to a
febrile condition.

In spite of this diagnostic insight,

purgation and bloodletting were considered to be the treatment of choice.

Still, oils and vJaxes continued to be the

foundation of topical therapy.

In 1858, the local use of

tannic acid was suggested in an attempt to coagulate the
vmund surf'ace._ln 1925,_Davidson (3) renev.Jed interest · in
the use of escharotics by the introduction of a tannic &eid
spray.,

It was believed at that time that tar..nic acid.!

t:::..ther

alone or in combination vJith silver nitrate, decreased fluid
loss, relieved pain, and produced an effective eschar.
\-.ras not until

194L~

It

that the use of tannic acid was abandoned,

when McClure determined that this agent was hepatotoxic (1,2)~
VJi th the advent of the sulfonamides, penicillins, and
other antibacterial agents, clinical trials

~11ere

initiated

in an attempt to decrease the incidence of deaths due to
burn \.Vound. sepsis.

HovJever, by 1953, studies demonstrated

that septicemia was still of primary concern and the most

3
common cause of death, even though supportive care \·Jas
instituted to prevent the shock associated with most major
burns.

In the 1960's, frequently implicated microorganisms

included species of Staphylgcoccus, Escherichia, Pseudomonas,
Aerobacter, and Proteus.

In addition, the major cause of

death in the severely burned patient had shifted from
Staphylococcal to Pseudomonas septicemia ( Li·-7).
Prior to 1964·, 60% of the burn patient deaths vJer.e
usually attributed to burn ,..,ound sepsis (8)"

Since that

time , invasive burn \IJOund infection has occurred at an
annual rate of 5-16%.

In burns of less than 30% body surface

area (B.S .. A.), death is an infrequent occurrence .

Ho,·.rever,

death occurs in 69% of those patients experi encing 50%
or more.

B.S~A ..

,

Of these , death can be attributed. to Pseudomona s

septicemia in 40% of the cases (4).

As more tt.en one million

people per year in the United States are burned badly ·enough
to warrant hospitalization, Goldman, IJarson, and Abst on (9 )
have described the burn injury as the

11

Silent Epidemic .. .,

This is evidenced by the fact that seven persons per 1000
population are injured by contact vrith hot objects..

Of

these, four deaths per lOO,QOO population can be expect ed ( 2 )9
General Cons iderations of the Burn Patient
In order to differentiat e the various depths of thermal
injuries , a commonly used classification divides burns into
three categories:
degree (2).

first degree , second degree , and third

First and second degree burns are fre quently

referred to as partial thickness burns , whil e the third. degr ee

lj.

burn is described as a full thickness injury .

The first

degree burn involves only the outer l ayers of the epidermis .
This burn is characterized by erythema that appears aft er a
short period of latency.

Tissue damage is quite superficia.l,

and because of this, minimal complications occur, except for
slight pain, erythema , and possible edema.

As this is a

very superficial thermal injury, the continuity of the skin
is not interrupted, infection rarely occurs, and healing is
usually uneventful.

\•J ithin several days, the burned areas

slough off in small scales ''Jith no long term effects (1) .
The second degree burn involves an entire segment of
the epidermis.

This partial thickness thermal injury can

be distinguished from the first degree burn by the pres ence
of

vesicles at the involved site.

Considerable subcutaneous

edema is · evident along with erythema and. :pain.

In the abs !?lee

of infection , he_aling will occur ,.,ithin ~eks as the
epithelium regenerates.

In the event o:f infection , a. second

degree burn may convert to a full thickness injury

\vit~

-the

characteristics and complications associated \vith this t;rpe
of thermal injury (1,2).
The third degree or full thickness burn may be a li fe
threatening injury.

Burns of· this type destroy the dermis,

subcutaneous tissue, or skeletal muscle resulting in possible
shock , septicemi a , and death.

In addition , thrombosis ,

increased capillary permeability, and edema surrounding the
burned area are indicative of a fu ll thickness burn .
the burned area appears dry, l eathery, and. cha rred .

l!urther,
Pa:in is

5
not an immediate factor, as the area is a lmost insensible
due to the destruction of the terminal nerve endings .

The

resultant dead tissue of the full thickness burn is referred
to as an eschar.

As the eschar consists of dead tissue with

no vascular supply, normal body defenses against infection
are r el atively non-existent.

For this reason, the prevention

of local infection and septicemia as a complication of a
third degree thermal injury is of prime consideration (1,2).
Initial bacterial grovrth usually occux·s on the surface
of the burn wound (4).

This groV<Jth is frequently referred

to as supra-eschar bacterial colonization.

This surface

grm·rth, if not arrested, is followed by intrafollicular
colonization into a reas of d.estroyed hair follic l es..

Once

this occurs, bacteria readily penetrate through the eschar
and then into subcutaneous tissues.

Bacteria.l infiltration

of these tissues is referrBd to as intra-eschar and
eschar colonization, respectively (2).
In addition to determining the burn depth and the

l~vel

of bacterial involvement, it is necessary to estimate the
extent of the injury prior to instituting appropriate therapeutic measures.

Traditionally, the "rule of nines" bas

been employed to provide an estimate of the extent of surface
area involvement.

This method considers the major body parts

as multiples of nine, allocating

9% to the head and neck , and

9% to each upper extremity. The anterior trunk, post erior
trunk, right and left lov1er extremity are each assigned lB% ~
with the perineum one percent..

As this s imple method of

6

estimation i s not totally accurate, other methods use
t ables describing surface area of body parts in relation
to age , height, and. weight.

Along vJi th the use of burned

surface a rea as an aid in selecting appropriate fluid
replacement therapy, the probability of survival can be
est imated wit hin reasonable limits, since s urvival is proportional to the extent of the thermal injury (1).
An older type of cl assification, described by Artz and

Reiss (10), suggest cat egorizing burns as minor, moderate ,
and critical.

f1inor burns include partial thickness thermal

injuries of l ess than 15% B.S. A., or full thickness burns of
less than 2%

B.S~A.

Partia l thiclcness burns of 15 to 30%

B.S .. A. and f ull thickness burns of less than 1096 are considered moderate burns, providing the hands, face, or
genitalia are not involved..

Critical burns a.r e those con:-

plicated by respiratory tract injury, full thickness burns
of the f ace , hands, or genitalia, full thickness burns

0::

more than 109.6 B.S.A., and partial thickness thermal injm·ies
of more than 3096 B.S. A.

In addition e l ectrica l burns, deep

acid burns, and those involving major soft tissue injury ruay
be categorized as critical burns.
As mentioned previously,

alterations in fluid and

electrolytes in the massively burned patient poses a life
threatening situation manifested as burn

shock~

Severe

thermal trauma results in a loss of circulatory int egrity
that culminat es in visceral failure a nd often death, unl ess
large volumes of biologically active fl uids are adininist ered ( 11) ..
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As part of the inflammatory response , local t i ssue damage
is a ccompani ed by increa s ed capilla ry p er meabi l i t y and
vas odilatation leading to a r a pid loss of f luid from the
circulation.

This escape of fluid produces local edema ,

hypovolemia, and decreased r ena l function.

Dist urbanc es

such as these will lead to alterations in el ectrolyt e and
protein concentration.

Although burn shock presents an

immediate hazard to the burn patient, effective therapeut i c
mana gement measures are available.

In a ll but the most

massive injuries, administration o.f adequate volumes of
plasma-, blood, electrolyte solutions, dextran solutions,
or a combination thereof, will enabl e the pat i ent t o overcome the stress o.f the situation

(4,1 2 ,1 3 )~

Current Practices in Loca l Th er apY
In an a tt empt to mini miz e and eradicate Pseudomonas
wound sepsis, topical therapy at the present time evolves
around the use of gentamicin sulfate,a mafenide acetate , ~
silver nitrate , and silver ·s ul fadiazine.

All of these

have demonstrated effectiveness in controlling invasive
vJound sepsis.

c:~en t s
~urn

None completely eliminate bacteria from t he

lesion, but will prevent extensive suppuration, especially
that due to Gram negative bact eria.
When 0. 5% aqueous silver nitrate is employed topically ,
dressings must be continuous l y s aturat ed in or der to k eep

a - Hereina ft er referred to as genta micin .
b - Hereina fter r eferr ed t o as ma fenid e .

8

this antibacterial in contact with the burn \.-Jound .

Us ua lly ,

dressings are moistened at two hour intervals, and a r e changed
every bwlve hours.

It should be not ed that t he hypotonicity

of silver nitrate can cause a severe degree of electrolyte
loss and, therefore , supportive therapy to avoid hyponatremia, hypochloremia, and hypokalemia must be considered .
The development of methemoglobinemia is a rare occurrence
that leads to discontinuance of silver nitrate therapy.
use of silver nitrate in established infections of

de ~p

The
t hird

degree burns is of questionable value since t he diffusibility
of this therapeutic agent is extremely lov1.

A further dis-

advantage associated with the use of silver nitrate involves
its instability upon exposure to light.

The deterioration

that occurs is manifested by the widespread s t aining of it ems
that come in contact with it (14-16).
The use of mafenide cream also greatly reduces Pseudomonas
sepsis.

However , use of mafenide can result in severe meta-

bolic acidosis secondary to its r a pid diffusion
burn wound. into the blood stream.

throu g~

-:b.e

I n high concentrations ,

rnafenide inhibits carbonic anhydrase which may lead to alt er ations in pH.

Therefore , while mafenide's deep percutaneous

absorption is of value in treating deep infections, i t may
pose systemic problems in the form of metabolic acidosis .

One

factor tha t has l ed t o a lack of patient acceptance is t he
moder ate pain that is experienc ed upon application of ma f eni de
cream to burns.

Alt.bough described as a moder at e pa in, cer tain

patients .r equire systemic analgesics to minimi ze this sid e

9
effect, and occasionally refuse the medication (14-17).
Silver sulfadiazine cream, an investigational drug
product, is currently being subjected to clinical study.
Clinical evaluation has identified

fe\'!

problems associated

\vith the use of this agent other than minimal percutaneous
absorption (14).
Gentamicin cream has rarely been implicated as a source
of drug related complications when used in burn therapy.
However, penetration to the dep·ths of the burn wound does
not occur to the extent noted for mafenide (14-16).
Although the above mentioned therapeutic agents have
been used successfully to treat Pseudomonas wound sepsis ,
concern has been expressed recently vJith respect to the overgrov~h

of non-susceptible organisms.

Further, pathogenic

fungi have been noted to colonize burn v10unds.

Because of

this, it has been suggested that the fungi have emerged as
a new infecti ous threat to the burn patient (14).

'l1o cm::bat

this, the use of povidone iodine ointment is presently -:.nciergoing investigation to determine i ts efficacy in

eradicat ~ ng

fungal infections of burn wounds (18).
In conjunction v:Tith the routine use of the above medicated
applications, supportive local care must be initiated in oro.er
to reduce the mortality associated with thermal i njuries..

The

primary goals of this care are the prevention of infection and
the clos ure of the lesion as soon as is possible.

For this

reason, removal of dirt and detached epithelium must be accomplished.

Initial cleansing of the burn with bland soap and

10

vmter will aid in t he removal of extraneous material .

Also ,

initia l excision of all dead t i ssue may be indicated since
devitalized tissue provides a n excell ent culture medium for
bacterial proliferation (2).
As pa rt of supportive l oca l care, the use of occlus ive
dressings, such as sterile gauze, petrolatum gauze, or medi cated gauze dressings may provide a beneficial effect.

The

occlusive dres sings are a bsorptive a nd, therefore, aid in
keeping the wound s urface dry.

Further, decreased conta!":!ina-

tion of the wound can be expected clue to the presence of a .
protective covering.

Hovrever, the use of gauze impregnated

with ointments can present certain problems.
Hagerty

(19)~

According to

drainage from the lesion may be inadequate and

occasionally result s in excess maceration and reduced epithelia lizati on.

The r eduction i n epithelial reeeneration and

the increase in maceration could produce a higher incidence
of infection.
In contrast to the u se of occlusi ve dressings, t he
exposure method has been described as a useful part of loca l
wound care.

By keeping the wound exposed, the exudat e on the

surface of the burn will dr y and form a crust.

Thi s

c r~st

s erves as a natural protecti ve covering for the wound and
epithelial regeneration may proce ed beneath the crus t unless
infection occurs.

However, this me thod requires that s pecial

provisions be made to ke ep the patient warm ( 20 ).
Removal of the eschar must also be accomplished as part
of the supportive local care of t he patient ( 2 ).

Although

11

some risk is involved, eschar removal i s a vital part of the
r epair and regrm·rth of the area .

Allowi:c.g the eschar to

remain in place can provide a culture media v1hich will per"·
mit rapid multiplication of bacter ia.

Further , an eschar

locali?.ed on the upper chest may inhi bit re spirat ion if ne-t
removed due to the constrictive action of the l esion

( 21~ 22) .

Techniques that a i d in the removal of the eschar include frequent changes of moist dressings, daily bathing in a Hubbard
tank, and surgical debridement.

A specific disadvantage o.f

the surgical procedure is the added injury and insult to the
already traumatized patient.

Complications include undue

hemorrhage ancl infect i on of the deeper layers of the ti ssue .
Soaking the patient in water at 100°lt utilizing a Hubbard
1

tank, although an effective method, involves the hazard of
spreading infecti on by the bath 'ltrater or associated equipment (2).
Topical Vehicles in Burn Therapy
Y.lith respect to the ointment bases in current

use~

tbe

traditional oil-in-water emulsion base has been select ed by
most manufacturers as the topical vehicle of choice in burn
therapy.

~1a.fenidea for topl.cal application is commerci a1ly

available as an ointment prepared in a water miscible emulsion base consisting of cetyl and stearyl alcohols , spermaceti ,
polyoxyl LJ.o stearate, polyoxyl 8 stearate, glycerin 1 ,.mt er and

a - Sulfamylon Cream, Winthrop Laborat ories , D.ivision of
Sterling Drug, Inc .. , New York, N. Y.
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suitable preservatives (23).

The vehicle for gentami cin

creama is describ ed as a bland emulsion composed of stearic
acid , propylene glycol monostearate, isopropyl myristate ,
propylene glycol , pol yoxyethylene sorbitan monopalmita te ,
sorbitol, and water (21.J.).

Nitrofurazone,b which has been

widely used in the treatment of infected lesions is present ly
marketed in two dosage forms.

The ointment formulation co:1.-

sists of gl ycerin, cetyl a l cohol, liquid petrolat um, an
ethoxylated fatty alcohol , preservat i ves, a.11d water (25) .

A

vmter soluble basec of mixed polyethylene glycol polymers is
also available for topical application of nitrofurazone .
Although presently avai l abl e for inve stigational use only ,
si lver sulfadiazine is also appli ed in an oil-in- water ernulsion base (26 ) .
In comparing the effectivenecm of an aerosol and tlrr'ee
creams containing 8.5% mafenide, Dressler et al (27) , mon itored both mortality rates and bacterial counts in burne·i
rats.

After burning each rat for ten seconds at a tempe:-·a ture

of 98°, d each animal was infected vli th one ml. of an l B r.ou1~
broth containing Ps. aeruginosa.

Three hydrophilic cream

vehicles containing stearyl .and cetyl alcohols,

g lyce rin~

a - Garamycin Cream, Schering Corporation, Bloomfield, N. ,J .
b - Furacin Topical Cream, Eaton Laboratories, Division of
The Norvli.ch Pharmacal Co., Norwich, N. Y,.
c - Furacin Soluble Dressing, Eaton Laboratories , Divisi on
of The Nor\vich Pha rma cal Co., Norvlich, N.. Y.
d - Hereinafter, temperatures are li s ted in degrees Centigrade.
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spermaceti ,

methyl pa raben, and propyl para ben were evaluated .

Sodium lauryl s ulfat e or one of t vJO other surface a ctive
agents , not designat ed , were included :in the cream bas e f ormul ations.

The a erosol was formulated in an undefinecl hydro-

philic ba s e .

The mor tality r ates in a ni mals treateo. v!ith the

mafenide creams ranged from 5 to 10%.

Util izing the corre-

sponding medicated aerosol, a mortality rat e of 20% v1as
obse rved.

Average mortality r ates for the nontreat ed con-

trols \'Jere 639&.

In addition, qualitative ba cteriologi ca l

studies of the seeded anima ls provided similar r esults .
Lindbei·g, Moncrief , and Hasan (28) utili zed twice da ily
applications of mafenide in a water soluble base consisting
of stearyl a nd cetyl alcohols , glycerin, and 62% y,rater .

A

rat model vJith a scald of 20% B.S.A. was u s ed to evaluat e t he
effectiveness of the product.

Untreat ed animals suffered over

90% mortality vJhile the treated groups survi v ed the Pseudomonas
challenge .

However, in animals treated only once a day Kith

the medicat ed cream, mortality rat es from 20% t o 40% ~e~e
observed .
A comparat ive evaluation of silver sulfadia zine and
mafenide in the burned rat model was performed by Dress l e r
and Skornik (29).
seconds in 98

0

After burning the backs of r ats for t en

.

water, the animals v1ere seeded \·lit h one ml .

of an 18 hour culture of Ps. aeruginosa .
initia ted two hours after seeding .

Topi cal

t h(:~rapy

vms

Monitoring mortality

during a 21 day study, it was found that ove r 909.6 of t he
ani ma l s in the control groups died .

The morta lity rate for

1'+

animals treated with 8. 5% mafenide c r eam wa s ll.J·. 59S, vJhile

20% of those treated with 30 mMoles of silver sulfadiazine per
k g. of Neobase Ointmenta died.

The medication was applied

onc e daily ru1d no attempt to remove the eschar or residual
ointment was made prior to treatment.

Subeschar ,

bl ood ~

and

liver bacterial counts were made .
Fox, Sampath, and Stanford (30 ) compared the effica cy
of silver s ulfadiazine and mafenide in ointments .

Burns

were produced by immersion of the dors um of rats for ten
seconds in water at 95°.

The animals were inoculated one

hour post burn vJith one ml. of an 18 hour broth culture of
Ps. aerugi_nosa.

Silver sulfadiazine, 1%, was applied bot h

in Neobase Ointment, and in a similar cream prepar ed specifically for the study.

Mafenide was used as the commer ci ally

a vailable Sulfamylon Cream.

Application of the test prepa.:·a.·-

tion and corresponding control materials were made once daily.
Using percent mortality

as the criteria f or evaluation, 92%

of the untreated controls and 100% of the Neobase t:rea:::ea..
animals died.

The mortality rate for animals treated vJi t h

maf enide was 12.5%, v1hile animals treated with the silver
sulfadiazine preparation suf,fered 11.2% mortality .

Postmortum

studied o.n tissues shovmd high bacterial counts in the untreated
controls but no positive blood cultures in the animals treat ed
with mafenide or silver sulfadiazine.
Using mice anesthetized v..rith ether and scalded in \·mter

a- Availa ble from Burroughs Uellcome and Co., Hesearch
Triangl e Park, N. c.
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at 68° for six seconds, Fox (31) determined the effect iveness
of various topical therapeutic agents effective against
Pseudomonas .

Local application of 0 . 5% silver nitrate solu-

tion or 8.5% mafenide cream reduced mortality from over 80%
to approximately 509G..

The topical applicati on of' an ointment

containing 30 mlV1ol e/kg . of silver sulfadiazine reduced mortality to approximately 20%.
Rosenthal (32) immersed mice to the upper third of the
thigh for five seconds in water at 70° to produce full t:C.ick-·
ness thermal injuries.

After infecting tbe burr..ed animals

with Pseudomonas cultures, several locally effective agents
v1ere eval uated.

Survival rates in those treated with mafenide

cream was 92% and in tho se treated \1/ith 0.14% chlora.mphenicol
in a similar base, 809G ..

Application of 0, 5;.6 gentamicin, 0 ./1-7~

neomycin, c:md 1% streptomycin gaye complete protection ..

A-nti-

biotics that were without therapeutic effect included p ol;ymyxin,
penicillin G, silver nitrate , and tetracycline ..
In a similar study by :!!'ox , Rappole, and Stanford C'53) ,
the tail, pelvis, and both hind legs of mice were immersed
for five seconds in water at 70° ..

After burning , the tail

vms immersed in a 1:1 dilution of an overnight culture of
Pseudomonas .

Topical therapy \vas initiated four to six hours

after infection and onc e daily thereafter.

Tbe percent mor-

tality for the untreat ed control s vJas 80%.

Treatment ;,vith

0.1% gentamicin cream or 8 .. 596 mafenide cream resulted in over
80% mortality.

The use of 1% silver sulfadiazine result ed i n

25% mortal ity.

It has not been determined i f this in vivo
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animal mode l uti l izine; tail inoculation was a factor in the
dramatic results obtain ed .
The us e of mortality rates as the primary c r i t eria of
effectiveness may pose prob l ems..

For example , in studying

bact erial infection in burned animals , it is necessary to
distinguish between deaths due to the trauma of the burn and
those resulting f r om inf ect i on with the test bact eria.

In

order to minimize death due t o the shock and trauma as sociated
vli th inflicting a l arge , f ull thicJ.r.ness, thermal injury,

McRipley and Garrison ( 34) suggest administ rat ion of f luids
to aid i n ove r coming the shock and trauma.

They a ccomplished.

burning by means of a steam chamber which consists of a metal
cylinder v.Ji th one side molded in the general shape of the back
of the animalo

The anesthetized anima l s v1ere placed. i n the

chamber and burned for 30 seconds.
In addition to the effect of shock and t rauma aftei' burni ng , the virulence of the test organism in the animal
may a lso affect the mortality r ates observed.

Fo}~

n~ oC. e l

(30) .found

that most strains of Ps. aeruginosa isolat ed from hospit alized
pat ients were l ethal to burned mic e but that rats were r elatively re s i s tant and di ed after seeding with certain strains
only.

Lindberg , Moncrief, and ~1as on (28) reported varying

morta lity r ates due to Pseudomonas virulence in burned.

rats~

In animals s eeded v-lith intensely virulent s trains (VA-13LJ-)
follo\IJed by once daily a pplicat ion of mafenide cream , mortality r ates ranged f rom 20% t o 4-096.

Ho-v.rever , all rats

seeded wit h a l ess virulent strain (12-4-4-59 ) and. treat ed
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in a similar manner survived.

Because of the va riable

effec t of virulence, shock , and trauma after burning , i t
may be of value to devise studies utilizing parameters based
upon the presence of the test microorganisms rather than the
fata l effect of their presence.
other Potentially Useful Dosar;e Forms
In spite of the refinements that have been made in ointments as a dosage form for the treatment of massive burns,
inherent disao.vantages are evident, especially vJhen app1ication to denuded areas is indicated.

As semisolid dosage for:n s

must be physically spread onto the involved site as a film,
it is possible that this application technique may result in
a painful experience for the massively burned patient .

Further,

the solubility characteristics of ointments may present prob·lems Hhen. efforts are made to remove the ointment .from the
denuded area .
In order to improve loca l therapy, several novel cpyroaches
to topical dosage form technology have been used.

P~ce7so~

formulated a water soluble protective f ilm for use on
areas such as a full thickness thermal injury.

(35)

de~uded

This formula-

tion consisted of cellulose.derivatives, glycerin, surfactants,
and

v~ater.

Upon casting and drying the film-forming solution,

the preparation appears as a highly porous film-like

banda~e.

In addition to its use as a protective· dressing, Anderson
suggests that medicated appl ications lvould be of value in
treating open skin l esions .
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t a 1s
· also a protective film for local use
V1.b esa-e

( 36).

However, this film is generated by means of a pressurized
aerosol.

This water insoluble mecha nical protective con-

sists of a n ethyl acetate-acetone solution of hydroxyvinyl
chloride acetate, modified rosin esters, and sebacic acid.
Although suggested for use on burns, skin ulcers, or other
injured areas, the solvent system of this aerosol produc es
transient pain upon application to sensitive surfaces.
Sciarra and Gidvmni (37) formulated 1rarious \<Jater insoluble, film-forming aerosols containing gentian violet.

Of

prime importance was the ability of a polymeric film to be
sprayed onto the skin and protect the skin against excessive
moisture loss .

Further, the ability of t he f ilm to facilitate

prolonged contact betv1een an active ingredient and the skin
was considered.

Acrylic and polyamide resins were used in

combination v1ith plasticizers, namely, tributyl citrate,_
hexadecyl alcohol, and lanolin derivatives.

The in v·-it-r-o

release of gentian violet from the films was determined .
Using similar film- forming aerosol formulations, Sciarra
and Gidwani (38) determined rates of drug release and magr..itude of binding to the film polymers.

Cetyl PJTidinium

chloride and benzalkonium chloride were selected as therapeutic agents to demonstrate the possibility of utilizing
an aerosol spray as a

11

spray-on bandage. 11

A mixed polymer

solution of a polyamide resin and ethyl c ellulose with

a- Availa ble from Parke, Davis and Co., Detroit, Mich.
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tributyl citrate as the plasticizer appeared to be best
suited for drug release.
Although not in use as a dosage form, Absorbable Gelati n
Spongea may be considered to be a type of dry foam (36,39 ).
This pliable aerated substance is cast from a treated gelat in
solution to render it insoluble in \vater.

As i t absorbs and

holds \'lithin its meshes many times its v.reight of whole blood ,
Absorbable Gelatin Sponge may aid in providing hemostasis
during surgery.
Becaus e of the disadvantages of ointments already
described, it may be assumed that they are not an ideal
topical dosage form for us e on the severely burned .p atient .
Therefore, using the conc ept of topical f ilms , it is the
purpose of this study to formulat e a topical medicament that
ma y be applied to denuded areas of the skin vlithout

inunc t ~_on ..

A further requirement is that the proposed dosage form be
highly \!later soluble, flexible, and adherent to both der;.!ld.ed
and intact areas of the skin.

Fina lly , it must be

de~c~

strated that it provides equivalent efficacy when coru:parsd.
to the ointment bases in current usage .
In order to develop a dosage form with those characteristics, it was decided to formulate a topical vehicle i n the
for m of a hydrophilic foam.

HO\·Jever, r ather than utilizing

an aerosol as the method of genera,ting the foam, a foam in
the form of an aerated, dry film vlill be compounded.

a - Gelfoam , The Upjohn Co., Ka l amazoo, I1'lich.

Once a
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suitable dry foam has b een formulated , both i n vitro and
in vivo evaluation s will be ma de to compa re the effective-n ess of medicated dry fo a ms with comrn8rcially available oint·ment preparat i ons.

EXPERII1ENTAL
Dry Foam Formulation
In developing a hydrophilic dry foam formulation for
topical use , combinations of ingredient s \•Jere selected on
the basis of their water solubility, foaming characteristics ,
and accepted usage in human subjects.

Based upon these

parameters,- many dry foam formulations were prepared, ev-aluated , and in most cases, rejected as a useful dosage form.
This information is summarized in Table I.
I n an attempt to provide optimal foaming properties,
surfactants, namely dioctyl sodium sulfosuccinat e,a polyoxyethylene so:r bitan mor1olaurate,b and f-1iranol 2111CA Modified ,c
were included in the formulations.

Dioctyl sodium sulfosuc-

cinate is a surface active agent that has been used as an
orally administered laxative and has been useful in a
of pharmaceutical formulations as a 1.-Jetting agent

vc~i et y

(36, ~-0) .

Polyoxyethylene sorbitan monolaurate, a nonionic emulsifi er ,
is used in the formulations of emulsions for both oral and
parenteral administration (36).

Miranol 2MCA Modified is an

amphoteric surfactant with detergent, emulsifying and wetting

a- Aerosol OT, American Cyanamid Co4, Wayne , N. J.
b - Tween 20, Atlas Chemica l Industries , Vlilmington, Del.
c - Availa ble from Tbe 1'-liranol Chemical Co., Inc., Irvington,
N. J.

TABLE I
Composition and Eval uation of the Experimental Dry Foam Formulations

Formulation
Nui-nbera

\r/ater

C- 1

Gross
Physical
Evaluation

Dextranb

Sor bitol
So ln.

Glycerin

45

30

19 . 5

11 . 3

C- 2

28

15

6. 5

3.9

C- 3

28

15

6.5

2

too porous

C- 4

28

15

6. 5

3

same as
C- 3

C- 5

28

10

6.5

C- 6

38 . 5

7

5. 2

C- 7

43 . 5

5

2. G

5

?.9

C- 8

LJ-2

I

I

D?Sc

T- 20d

Niranole

1

slowly
soluble;
sticky

0 . 25

sticky

l

more
flexible
and less
sticky
than C- 1

0.5

similar to
C- 3;
slightly
sticky

0.25

too

0.2

too

fragile
fragile

f\J

i\)

TABLE I (continued)
Gross
Physical
Evaluation

Formulation
Numb era

Water

C- 9

20

4

1. 3

I

0. 1

insufficient
plasticity

C- 10

20

4

2.6

I

0.1

good
plasticity ;
non- sticky;
liquefies
quickly

G- 11

19

4

2.6

0.1

same as C- 10

C- 12

19

4

2.6

0.05

same as C- 10

C- 13

19

4

2 .. 6

0 . 02

insuf ficient
aeration

C- 14

19

4

2. 6

0 . 05

same as C- 10

Dextranb

Sorbitol
So l n .

Glyceri::J.

D)Sc

T- 20d

Miranole

a - Quantities are li sted in g .

b - Dextran T 70 was used as t he dextran componsut for all formulations except fo r C- 14.
Sigma Dextran was used i n C- 14.
c - Diocty1 Sodium Sulfosuccinate .
d. -

Tween 20.

c -

I'-Ii r~'1o1 2 l"'~CA

fviodified.

PJ

·~

properti es (41).

As t hi s agent is non-irritating to skin

and mucous membranes , it is frequently included. in "no sting 11
shampoos ( 42) o

The lO\tJ order of t oxicity and high foaming

pov:er of these were essential considerations in their selecti on for the experimenta l product.

In order t o pr ovide a hydrophilic base or matrix for the
dry foam, Dextran T 70,a and Sigma Dextran,b with an average
molecular v1eight of 86,900, \'Jere included in the experimental
f ormulations.
of glucose.

The dextrans a r e free l y water soluble

polJ~ ers

Thera peutic indications fo r Dextra n 70 include

the intravenous infusi on of a

6%

s olution as a plasma expander

in the prevention or treat ment of hypovolemic shock (36, 4-0 ).
For added plasticity upon drying , 70% Sor~it ol Soluti on ,c
. d
U•S•P• , a n d Glycer1n,

u•s•p• , were 1nc
. 1 u d e d 1n
. var1ous
.
i :ormu'

lations .

Along with its use as a humectant and sv1eeten er ,

Sorbitol,

u.s .. P.,

has been used as an osmotic diuretic admin-

istered intravenously as a 50% solution.

Glycerin is a

pharmaceutical solvent useful as a humectant and emoll;i.en7;
in topical preparations ( 36 ).
In addition to variations in composition, variati ons in
formulation techniques were made, such as drying conditi ons ,
blending time , dissolution temperature, moisture c ontent , and

a -Available from Pharmacia Fine Chemicals, Piscataway, N.. J.
b - Available from Sigma Chemical Co., St. Loui s, Mo .
c- Sorbo Solution, Ruger Chemica l Co., Inc .. , Irvington, N. J.
d - Ava ilable f rom Ruger Ch emica l Co., Inc., Irvington, N. J-..
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thickness of the cast foam..

Bas ed upon s ubj ective

the most promising dry fo am fo rmulation ,

C-- lL~,

eva l uation ~

Has sel ect ed

for furt her study in orde r to compare it s effectiveness vJith
ointments as a dosage form for topical application of c ommon
agent s used in local burn therapy.

Formul ation C-14 consists

of the f ollowing:
Sigma Dextran • • • • • ~ • •
Sorbitol Solution, U. S. P • • •
l1iranol 2l\1CA f\1odified • • • •
'vlater • • • • •
..
•

0

...

. ..

4 .. 0 g .
2.6 g .
0.05 g.
19 .. 0 g .

The dextran v.Jas dissolved in 19 g . of vmter at a temperature
of ?0° to 75° on a water bath..

The remaining ingredients were

addeo. and the entire solution \\•as whipped i:'or ten minute s with
an electric beater .

The resultant foam was cast on a teflon

coated pan to a depth of tv:o mm., and dried at a temperature
of 40° to L;..5° for 20 t o 30 minutes in a laborat ory oven.
After drying , the moisture content of the dry foam '"'as deter-mir!ed using a Genco Moisture Balance .. a
these mea surements were 10%.

Average values .for

In addition t he

time of the dry foam was determined..

liqu e.fact.:.~n

It was deter mineC. tb.at

2.5 e m. 2 of the dry fo am liquifi ed in 0.1 ml. of wate:r· at
ambient temperature in 20 seconds.
Batches of t he dry foam formulation v1ere prepared con-taining each of the f ollowing t her apeuti c agents in t he
concentration listed:

8 .. 5% mafenide, as the acet ate; b 0 . 2%

a- Centra l Scientific Co., Chicago, Ill.
b -- Sul.famylon Powder, Sterl.ing-ltlinthrop Res earch I nstitute ,
Rensselaer , N. Y.
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nitrofurazone;a 0.196 gentamicin sulfate;b 0.5% silver
nitrate; c and , 1, 2, and 3% silver sulfadiazine.

According

to the method of Fox (31,43), silver sulfadiazine wa s prepared by mixing 27 g. of sodium sulfadiazinec with 17 g. of
silver nitrat ec in 100 mls . of water.

The precipi tate v;as

washed, coll ected, and dried to constant Vle i ght at a temperature of 50° to 60°.
Visual observation of the medicated formulations b efore
drying shov1ed that the nitrof urazone and the silver sulfadiazi ne preparations appeared as light, fluffy, i'irm , foams
similar to that of· the nonmedicated C-14 formulation.

How-

ever, the mafenide, gentamicin , and si lver nitrate formulat j ons
did not have this c onsistency.
mixture appeared slightly fluid .

Rather , after

blending~

the

In spite of this altered

appearance , all medicated i'ormulations were cast and d r i e d.
as ahove, and s_u_hjected to in vitro testing.
In Vitro Evaluation
As Ps. aeruginosa has been frequently implicated a2

~h e

causative bacter ia· in burn vJOund sepsi s, a modified microbiological agar diffusion test was utili zed to compare the
effectiveness of the dry foam vlith ointments as a vehicle
for therapeutic agents effective against this bacteria (44).

a - Furacin c·rystal s , Eaton Laborat ories, Division of I11ort onNorwich Products, Inc ., Norwich , N. Y.
b - Garamycin Injecta ble, Schering Corporation, Bloomfield,
N. J •

c- Availabl e from Ruger Chemical Co. , Irvington, N. J .
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The in vitro ef fectiveness of the medicated dry fo a m
preparations was compared with the corresponding commercially availabl e ointment formulations, namely, mafenide

· J..n
· cream. c
cream, a n1.·t ro f ura zone cream , b and gent amJ..c
Although not commercially available, 0 .5% s ilve r nitrate
in Neobase Ointment,d and 1, 2, and

3%

silver sulfadiazine

in Neobase Ointment 1t1ere prepared extemporaneously and
utili zed in this study.
After autoclaving sufficient quantitie s of Bacto
Antibiotic Medium 2e at 121° and 15 psi for 25 minutes in
an autoclave, approximately 20 mls. ,llere poured into
100xl5 mm. sterile disposable petri dishes .

Upon congealing,

0.1 ml. of Bacto Antibiotic I·1edium 3f containing an overnight
inoculum of Ps. aeruginosa (A.T.C.,C .. No. 972l) g ,.ms spread
onto the agar media with the aid
rod.

Oj':

a

steril ~:: ,

L-sbaped glass

Using a syringe, each of fifteen penicylinders

wa~

filled with approximately 0. 3 g . of the ointment forrrnll2.:;i on

a - Sulfamylon Cream, 'vlinthrop Laboratories, Division cf
Sterling Drug, Inc., NevJ York, N. Y.
b - :B'u racin Topical Cream, Eaton Laboratories, Division of
The NorvJich Pharmacal Co .. , Norwich, N.. Y.
c - Garamycin Cream, Schering Corporation, Bloomfield, N. J.
d - Available from Burroughs \'lellcome and. Co., Research
Triangle Park , N. c.
e -Available from Difco Laboratories, Detroit, Mich.
f -Available from Difco Laboratories, Detroit, Nich.
g - American Type Culture Collection, Rockvill e , Md.
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under investigation.

Penicylinders \·Jere pl ac ed upon the

seeded agar, and incubated overnight at 37° .

Penicylinders

filled v1ith Neobase Ointment s erved as the control .

Zones

of inhibition vJere measured after 24 hours with a li'i sher-LiJ.ly
Antibiotic Zone Reader ~a
The medicated dry foam formulations were . evaluat eO. in a
similar manner.

However, rather than utilizing penicylinders .,

f ift een discs of each medicated dry foam were prepared,

e ac~

with a diamet er of 7 mm. -- approximately equal to the diameter of t he penicylinders .

Nonmedicated dry foam discs \·!ere

also prepared a nd evaluated as the dry foam control .
As no zones of inhi biti on were not ed for the control s,
this informati on is summarized in Table VI I I , while the
result s of the in vitro determinati ons for the medicated
dosage forws are list ed in Tables II-VIII ..
Preliminary Stability Studies
Prel imina ry tests were initiated in order to deterDi nc
the stabi l ity of the dry foam.

As a result of the in vi.tTo

evaluations , it appeared that two types of o.ata were obtaiDed ..
One type, the mafenide and gentamicin Cl.eterminations , d e!!lon-·
strated equivalent release from both the ointment and dr y
foam formulations.

The other type, the silver containing

preparations , demonstrated greater release f'rom the dry foam
. b an t-l1e correspond J.ng
.
. t ment s.
oln

t;

}~!

. reason , 8 • 5q
or th ls
pl

mafenide and 2% silver sulfadiazine v.Jere sel ected .for furth er

a- Fisher Sci entific Co. , Pittsburgh, Pa .

TABLE II
I n Vitr o I nhibi t ion of Ps . · aerQginosa By Dry
Foam and Ointment Containing 0.5% Silver Nitrate
Diameter~

Plate Ng_.__ ~ ~~ __
1

0.5% Sil ver Nit rate
Dry Foam
15.6
10.2

2

13.0
12.2
12 . 6
13 . 2
14 . 0
14 . 0
10 . 8

3
Lf.

5
6

7
8

9
10
11
12
13
14

Zone of 1nhibition(mm)

0.5% Silver Nitrate
Oi ntment

9 .. 6
12 . 2

9 .. 4
9. 4
8.0

7. 5

1L~ . o

8.4
10. 0
8. 6
8. 8

13 .2

9. 1

1L~ .. 8

8.0

1p . s

9. 8

lO.L~

10 . 6

15

13 . 0

9. 6

Mean
Standard Deviation

1b.s

9 .. 3

~ ,. 6

1. 2

p

<

0 . 001

1'\)

\..0

TABLE III
In Vitro Inhibition of Fs. aeruginosa By Dry
Foam and Ointment Contair.ing 1% Silver Sulfadiazine
D.iamet er, ~Zone~o.f- I!i..h.Tbi-Fi on-(!Pin)
Plat e No .
1
2

3
4

5
6
7
8

9
10
11
12
13
14
15

l\1ean Diameter
Standard Deviation
p < 0 . 001

1% Silver Sulfadiazine
Dry Foam

1% Sil ver Sulfadiazine
Ointment

16.6
14. 0

7.0
7.8
8. 0
8.6

18.4
15. 0
16.0
16.0
17.8
19. 0
18. 0
18 .. 6
15. 0
19.0
17.0
18 . 0
19 .l~

17.2
1. 7 .

7.8
8.8

9. 4
9. 4
8.6
8 .v
()
11. 6
9.0
8.2
7 .5
7. 9
8 .. 5
1.1

'->!

0

TABLE IV

In Vitro Inhibition of Pse aeruginosa By Dry
Foam and Ointment Containing 2% Silver Sulfadiazine
Diameter;-uzone -of~ Inhibition(mm)
2% Silver Sulfadiazine
Dry Foam

2% Silver Sulfadiazine
Ointment

7

16.0
20.7
14-.0
18. 0
17.6
15.0
17. 8

8

16.3

9 .48 . 48.410.49.2
10 .. 0
10.6
11.0

9
10
11

15.2
16 .. 420 .. 4

12

16.4

13 .

1415

17 .. 2
15 .. 1
13 .. 2

I11ean

l6 L6

Plate No.
1

2

3
45
6

Diameter
Standard Deviation
p < 0.001

2' ,

·~

8.8

10.49 . 49 .6
9. 0
11
c;
--•/

9 .0
9 .7
0 . 0./

\..'I
1-'

TABLE V
In Vitro Inhibition of Ps. aeruginosa By Dry
Foam and Ointment Containing

3% Si lver Sulfadiazine

----

- ----~-

-

~-

-

-- ~-{.-- -:;::::-'\

Di ameter, Zone of Inhibition\rnm;

Plate No.
1
2

3%Silver

Sulfadiazine
Dry Foam

9
10
11
12

20.0
20 . 0
23 . 0
21.4
20 . 4
22.8
17.2
20.6
22 . 0
21.6
18.0
22.8

13

19.5

14
15

19.0
20.2

3
4

5
6
7
8

Mean Diameter
StandarQ Deviation
p < 0 . 001

20 .. 6

-· 7
l

I

3% Silver Sulfadiazine
Ointment
10 . 0
10 .. 6
11.0
8 .2
8.6
8.6
9 .6
10.8
9.2
11.2
9. 0
10 . 0
10 . 8
8. 0
10. 2
9 .7
1.1

\.,'-J
f\)

TABLE VI
In Vitro Inhibition of Ps. aeruginosa by Dry
Foam and Oi ntment Containing

8.5% Mafenide

--Tiiameter, Zone

8.5%

Mafenide
Dry Foam

Plate No .
1

26.0
28 . 5
28.0
28.5
29.0
27.0

2

3
Lj.

5
6

7
8

9
10
11
12

13
14

15
i1 c a n Diameter
Sta ndard Deviation
P (Cal )

0~05

of~rih.Ibl.tion(ffim)

8 . 5% Mafenide
Ointme_nt
24.0
26.2
24.2
26.2

27 . 5
27 . 5
26.5
25. 0
20 .. 0

26 . 4
26.2
26.8
26.0
27 . 0
24.4

30.0
29 . 0

25. 6
26. 4

2? . 0
2 9 .0

26.2
26. 4

27.2
2 1J..

.

25. 9
1.0

\>J
\..'l

TABLE VII
In Vitro Inhibition of

Ps~

aeruginosa By Dry

Foam and Ointment Containing 0.1% Gentan:.icin
Diameter, Zone of Inhibition (mm)
Plate No.
1

2

3
4

5
6

7
8

9

0 .1% Gentamicin
Dry Foam
11.0
11. '-i13.0
13. 5
10. 8
10 .2
10 . 0
13.6
1'+. LJ-

10

]_lj. .

1,

12
13
14

12 . 8
12 . 6
12. 0
12 .. 0

15

12 ~ 0

...........

6

0 .1?6 Gent a:ni cin

Ointment
15.2
13.0
12 . 0
14.6
14 .6
12.6
11.0
1L~.s

15.5
15 .2
13.2
11.0

\.}J

1·1ean Dia:net er
Standar d Deviation
p < 0 .. 1 > 0. 05

12 . 3
1. '+

1 3.6
1.6

-!==-

TABLE VIII
Summary of In Vitro Hicrobiological Evaluation of Nedicated Dry Foams and Ointments

Formul ation

Mea..."'l Diameter, a
Zone of Inhibition(mm2

Standard
Deviation

12. 8
9.3
17.2
8 .5
16. 6
9. 7
20.6
9.7
27.2
25.9
12.3
13 . 6

1.6
1 .. 2
1.7
1.1
2.1
0. 9
1.7
1.1
2 . 41. 0

p < 0 . 001

1..4-

p < 0. 1

0.5% Silver Nitrate Dry Foam
0 .5% Silver Nitr ate Ointment
1% Ag Sulfadi a zine Dry Foam
1% Ag Sulfadiazine Ointment
2% Ag Sulfadiazine Dry Foam
2% Ag Sulfadiazine Ointment
3% Ag Sulfadiazine Dry Foam
3% Ag Sulfadiazine Ointment
8 . 5% Mafeni de Dry Foam
8 . 5% Mafenide Ointment
0. 1% Gentamicin Dry Foam
0.1% Gentamicin Ointmentb
0.2% Nitrofurazone Dry Foamc
0 . 2% Nitrofurazone OintmentC
Dry Foam Controlc
Neobase Ointment Contro1c

.:1 -

1. 6

Stu.d.ent t

p < 0 . 001
p < 0.001
p < 0.001
p

< 0.1 > 0 .05
> 0 . 05

Results listed are aver age val ues for fifteen determinations .

b - Gentamicin Ointment liquef'icrl ut t ho incubation t emperG.ture .
c - No zones of inhibition observed.

\.N
\}1
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study, as they appea r ed to be representative of the tvTO
types of in vitro data obtained .
.

0

These two formulations
0

0

0

'l'l ere subJect ed to storage at -·5 , 5 , 25 , and LJ-5 •

In

order to determine t h e effect of var ying levels of humidity at
these temperatures, the medicated dry foams were stored in
three different humidity s ituations , namely, dry, ambient,
and saturat ed .

A dry environment \.Jas created by placing the

dry foams into open one-half ounce ointment jars , and pla cing
these into tightly sealed two ounce oint ment j ars containing

0.5 g. of the dessicant, calcium sulfate.a An ambi ent humidity
environment was provided by placing the o.ry foams int o
containers

,.,it hout

dessicant .

si~:i. lar

A \'Jater saturated condition

· wa.s created by pl a cing t he dry foam s into ouen one -ha l f ounce

ointment jars and placing these into tightly sealed tvm ounce
ointment jars containing approximately 20 ml . of vmt er.
Dhysical

~ruination

Gross

of the samples was made daily to deter-

mine the effect of storage upon stability.

The results

~f

this ·study are list ed in Table IX.
As the ingredients of the dry foam formulations are
freely water soluble, it was asswned that storage in a tight,
light-resis tant container," such as an ointment jar, would
prevent or minimize any advers e effects that moisture ma y
have upon the formulations.

However, as liquefaction occurred

vJith a ll but two of the samples t ested, it was a ssumed that an
ointment jar, although a tight container, do es not prevent

a - Drierite, Vl. A. Hammond Dri erit e Co., Zenia, Ohio ..
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passage of moisture.

In addition, the a d.visability of

maintaining 10% moisture in the dry foam was determined
during the formulation of various experimental dry foams .
Since loss of this moisture vJOuld result in an undesirable
preparation, further stability studies were indicated to
determine the extent of moisture loss from the dry foam at
elevated temperatures.
A second attempt \o<las made to d:evise optimum packagil:g
a nd

sto~age

conditions utiliz.ing sealable , moisture- proof,

p l astic bags.a

In this studys mafenide and silver sulfa-

diazine dry foams were stored in individual bags a t -5°,

5°, 25° , 35°, and LJ-5° at a mbient humidity.

The results of

this study are listed in Table X.
In Vivo Eva luation
In order to d.evelop suitable in vi V.Q t ecb..niques , s even
male, albino guinea pigs \'Jere subject ed to various bu.rni q;
and treatment techniques .

Based upon this pre limir..a::'7 -..-·:J::-k,

a burning procedure was devised utilizing steam

projec~e~

through an orifice approximately 8 mm. in diameter.
backs of the a nimals -v1ere clipped with a hair clipper

The
a..~O.

shaved with an electric shaver under l ight ether anethesia .
Each animal v..ras then \veighE.d.

Appoximat el y 24 hours aft er

shaving, four burns -vrere inflicted upon the back of each
animal while under ether anesthesia.

Steam at a temperature

of 80° to 90° vms directed onto the backs of the a nimals for

a - Ziploc Bag s, Dov.,r Chemical Co .. , 11Iidland,

~1ich.

TABLE IX
Shelf Life of Medi cated Dry Foams During Storage in Ointment Jars

Temp
(°C)

2% Sil -_rer Sulfadiazine Dry Foam
B--:-5-Sb Nafen~Cie Dry-7oam
I Storage Environmenta
Dry
Ambient
S~.turated
Dry
Amb i en-G
Saturated

-5

0
60+

14

1

30

14

1

5

60+

21

1

21

14

1

25

14

2

1

2

2

1

45

2

2

1

2

2

1

a - Samples of each formulation wer e placed into ointment jars and stored in the dark
at the temperatures and environments indicated.
b - Shelf life in days as determined by gross physical examination.

\}>;
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TABLE X
Subjective Evaluation of Medicated Dry Foam After Storage in Plastic Bags
Storage Temperaturea
(°C)

Formulationb
2% Ag Sul~adiazine Dry Foam
8.5% Mafenide Dry Foam

-5

Li quefaction after 4 weeks

Liquefaction after
four \•reeks

5

Integrity retained after 4
months

Int egrity retained
after LJ- months

25

Integrity retained after
months

Liquefaction after
8 weeks

35

Loss of moisture, loss of
flexibility after 1 week

Loss of moisture, loss
of flexibility, color
change after l week ·

45

Loss of moisture, loss of
flexibility after 1 week

Loss of moisture, loss
of flexibilit y , color
change after l week

L~

a - Sa."llples of each formulation vJ€lre placed int o sealable~ moisture- proof plastic bags
and stored in a dark environment at the temperatures indicated, at ambient humidity.
b - Each formulation was inspoc-t od at

\-Je c~kly

intervals for 4 months .

\.,'\l

,_o

L~O

a period of ten seconds in orc1er t o obta i n :four full thickness
injuries, each approximately 8 mm. in diameter.

The animals

\rJer e then returned to indi vidua l cages with ample food and
\'lat e r and ob served for 24· hours.

After this period of time,

each burn was inoculated by S\•Jabbing \vith an overnight broth
culture of Ps . aeruginosa.

Therapy \r.JaS initiated 30 minutes

after infecting the burn s a nd repeated every tHelve hours
thereafter.

Prior to the a pplication of the dosage

for~

under investigation, the backs of the animals Ne:re moistened
by

the use of a nebulizer containing deionized water to

facilitate adherence of the dosage form to the vi01Ll1d .

In

addition , cultures of the burns v-Tere obtained with stcrilG
swabs moist ened \'lith sterile water at these time intervals
to det ect the presence of Ps •. aer uginO ?.§:.•

Demonstration of

the appl :Leation and liquefaction of the medicated dry foa:1
is illustrated in Plate I .
As mixed coloni es v1ere cultured from the burn c.:r-ec.s,
appropriate identification tests \•Jere performed in
distinguish Pseudomonas from other bacteria.

c~C..e::

to

Initial

differentiation was made by the use of the Gram stain, since
PseudoiB.smas is a Gram-negati,ve ba cteria

(L~5).

Secondly, the

a bility of Pseudomonas species to produce a diffusible bluegreen pigment, pyocyanin, a l s o a ided in the identification
procedures (46).

In addition most strains e l aborate another

pigment knovm a s pyoverdin or fluorescein (45-4·7).

According

to Ward et al (48), f luoresc ein produces fluorescence upon
exposure to ultra viol Gt light even in the presence of oth er

bacteria.

This fluorescence has been used in the clinical

diagnosis of the onset of Pseudomonas burn sepsis.
reason, a short vmvelength ultraviolet lamp

a

For this

was used as an

aid in identifying and quantifying Ps._ aeruginosa. isolated
from the guinea pig burn areas.

Demonstration of the fluo-

rescence of Ps* aeruginosa can be seen in Plates II-IV.
Once isolation and identification of the Gram-negat ive
bacteria were accomplished, visual examination permitted the
differentiation of three types of bacteria, namely, flu ores·cent, diffusible, pigment-producing colonies; ivory-colored
colonies; and yellov1-orange colonies.

Further identifica-

tion tests were performed on representative samples of these
three Gram-negative bacteria in oro.er to substantiate the
identification.

Identification of Ps .. aerug-inosa can be

accomplished by the u~;e of several biochemical tests (49--51) ..
Of

tbes ~,

test s_tor oxidase, and indole, were selected to

differentiate the test organism from the other

Gram-~e€ative

bacteria isolated from the animal burns8

1.

Test For Oxidase

Patho Tee - COb test papers were used
to detect the presence of cytochrome
oxidase. Usi~ g a platinum loop smear
some of the suspected colony across the
moistened test paper. The presenc e of
oxidase is indicated by the appearance
of a blue color.

a - I1inera light, Ultra-Violet Products, Inc .. , San Gabrie l, Ca.
b - Available from General Diagnostics Division, HarnerChilcott, Morris Pl ains, N. J.

Appearance of Burn on
Guinea Pig

2L~

Hours

· Placement of Medicated
Dry Foam onto Burn Area

After I njury

(Time = 0)

Ee.rly Stages of Lique-

Complet e Liquefaction

faction (Time = ·5 sec)

(Time = 10 sec)

L

Plate I .

Application and Liquefaction oi'
f1edicated Dry Foam In Vivo

4-4

45

Plat e I I .

Fluorescence of Ps. aeruginosa In Vivo

Legend:

I = Culture From Infected Untreated Burn
U

= Culture

From Uninfected Untreated Burn

OB = Culture From Infected Burn Treated With 8.5% Mafenide Ointment
FB = Culture From Infected Burn Treated With 8.5% Mafenide Dry Foam

Fluorescent Light Source

Ultraviolet Light Source
\'lith Yellow Filter. Note
Fluorescence in I. Use of
Yellow Filter Facilitates
Visualization.

Ultraviolet Light Source.
Note Fluorescence in I • .
Blue Light Source Prevents
Optimal Visualization.

Plate III .

Fluorescence of Ps . aeruginosa Cultured From In Vivo Maf enide

St udy at 108 Hours

.;:=--..:3

Fluorescent Light Source

Ultrav~ olet Light Source
With Yt llow Filter; Note
Fluore~cence Along Upper
Edge o~ Eschar • . Use of
Yellow! Filter Facilitates
Visualization.

Ultraviolet Light Source;
Note Fluorescence Along
Upper Edge of Eschar. Blue
Light Source Prevents
Optimal Visualization.

Plate IV.

Fluorescence of Ps . aerug;nosa on Nine Day Old Eschar

-t:-

\..0
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2.

Test For Indole
Kovac's Reagent
Paradimethylaminobenzaldehyde
5 g.
Isoamyl alcohol • • • • • • • 75 ml.
Concentrated Hydrochloric Acid 25 m1 .

Dissolve the aldehyde in the alcohol by gentle
Harming in a 500 vJate r bath. Cool and a.dd tbe
acid .. . Store in a dark bottle at 40. Ad.d 0 . 5
ml. of Kovac's Reagent to a 1-2 day peptone
water culture. A posi ti v·e reaction for the
presence of indole is indicated by the pre sence
of a pink color.
The results of the identification tests are list ed in
Table XI.
In Vivo Evaluation -

~1afenid e

As tbe in vitro studies \•lith mafenide produced the
largest zones of inhibition, in vivo evaluation of the dry
foam and ointment \vas perfo rmed utiliz'ting this therapeut i c
agent.

In order t o compare the effectivenBss of the dry

foam containing 8 . 5% mafenide \'lith the correspond...ins ointment, fi fteen male guinea pigs, each weighing approrima-::-ely
300 g .. v.rere randomly selected for study , after keepin.s
i n individual cages for at least one week.

-:;nem

During the course

of the study each animal vms provided with ample food and
wat er..

Each animal \•!as shaved, weigb.ed , and burned i n the

manner previously described.

Tv;enty-four hours aft er burn-

ing , three of the burns were inoculated by S\vabbing with an
overnight broth cul ture of Ps. aeruginosa, \·Thile the fourth
area on each ani mal served as the burned, uninfected control.
Of the three infected areas , one was medicated with 0 .1 g. of
the mafenide ointment appl ied by means of a tongue depressor .

TABLE XI
Results of Microbiological Identi f i cation Test s
IdentiJI~c-ati

Organisma
Ps .. a.eruginosa, A.T.c.c. 9721
Unknovm (fluorescent)
Unknovm (ivory)

on-'1' est

Gram Stain

Indole

GAi dase

Fluorb

Pigmentc

-

-

+

+

+

-

+

+

+

+

Un.."k:no,·m (yellow)

a -

Unkn o~m organisms were isolated from burn wounds during in vivo studies .
Representative samples of these were subjected to the tests indicated.

b - Fluorescence was observed using ultraviolet light.
c - Production of a diffusible . pigment indicates a. positive result.

\.Ji
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The

area was medicated with the mafenide dry fo a m,
applied in the form of 2.5 cm. 2 • The third area served as
~econd

the burned infect ed control.

Swab cultures I•Tere obtained

and therapy vJas continued every twelve hours for 156 hours
(6 l/2 days).

Positive cultures v1ere considered to be those

in Nhich five or more colonies of the test organism were
isolated and identified. · The results of this study are
li sted in Tables XII and XIII and are illustrated in Fi gure 1 ..
In Vivo hvaluati on - Silver

Su lfadiazin~

Of the three concentrations of silver sulfadiazine oi ntment tested by the in vit ro methods , the 2% preparation appeared
to be the optimal concentration.

Because of this, the relative

in vivo effectiveness of the dry foam as a topical dosage form
in comparison to the ointment was determined using this the r s.peutic concentration.

Fifteen male guinea pigs, each weighing

approximately 400 g., \vere randomly select ed for study ., after
keeping them in individual cages for at least one

week~

Each

animal was provided v1ith ample food and water during t he course
of the study.

Each animal -vms shaved and burned in t he pre-·

vious ly described manner..

Each of the four burn areas '\<:a s

incoulated by mmbbing \•lith an overnight broth culture of the
test organism and assigned therapeutic regimes as .follov!S:
0.1 g. of 2% silver sulfadiazine in Neobase Ointment; 2.5 cm. 2

of 2% silver sulfadiazine clry foam; 0.1 g. of the Neobase
Ointment as the control; and 2.5 cm. 2 of the non-medicated
dry foam as a control..

This therapy was continued every

twelve hours for 72 hours.

In addition, swab cultures were

~ABLE XII

Mafenide Therapy of Burned Guinea Pigs at 156 Hours

I
No. of Pdeudcrnonas Coloniesb After Treatmentc With
Animal Numbera

Mafenide
Dry Foam

I'1afenide
Ointment

1

ad

0

+++

2

0

0

0

+++

3

0

0

0

+++

4

0

0

0

+++

5

0

0

0

+

6

0

0

0

+++

7

0

0

8

0

0

0

9

0

0

0

+++

10

0

0

++

+++

11

0

0

0

+ ++

12

0

0

0

+++

13

0

0

+++

+++

I

Uninf
Control

+

Inf
Control
+

+++

\Jl

\ .)-J

TABLE XII (continued)

No . of Pseudomonas Coloniesb After Treatmentc 1• /ith
1

Nafenide
Ointment

Mafenide
Dry Foam

Animal Nurnbera

Uninf .
Control

Inf.
Control

14

0

0

+++

+++

15

0

0

+++

+++

Total

0

0

6

I

15

a - Each of fift een animals rec eived four full thickness burns . Three of the four
burns per animal were inoculated \vith an overnight culture of Ps . aeruginosa .
b - Cultures of each burn were obtained every 12 hours for 156 hours "~:lith sterile
swabs moistened with sterile water. Plat ing and incubating of the cultures
were followeo. by isolation and identification of the bacteria .
c - Treatment consisted of 8.5% Mafenide Ointment or Dry Foam , applied to the
involved site every twelve hours ffor 156 hours . In addition, one burn per
animal served as the uninfected , untreat ed control, and one served as the
infected, untreated control.
d - Code:

0
+
++
+++

=

0- 4 Pseudomonas colonies isolated and i dentifi ed from each burn.

= 5- 10 Pseudomonas colonie s isolated and identified from each burn.,
= 11- 20 Pseudomonns colonies isolated and identified from each burn .
= 21 or more faourioinonas colonies isolat ed and identified f rom each burn.
\Ji

.;::

TABLE XIII
Results of Mafenide Therapy of Burned Guinea Pigs
. a
TJ.me

Number of Anima1sb \vith Positive
d
Pseudomonas Culturesc After Treatment With
r1afenide
Dry Foam

Maf enide
Ointment

Uninf.
Control

Control

12

14

4

2

15

24

1

l

5

15

36

0

0

6

15

L~8

0

0

5

15

60

0

0

8

15

?2

0

0

8

15

84

0

0

8

15

96

0

0

10

15

0

0

5

15

120

0

0

8

15

132

0

0

8

15

(hr )~-~-- _

108

I

Inf.

\.i1
\.,,'1

TABLE XIII (continued)
.
a
Ti me

(hr)

Number of Animalsb \'lith Positive
d
Pseudomonas Cult uresc After Treatment With
I"lafenide
Dry Foam

Hafenide
Ointment

Uninf.
Control

Inf.
Control

144

0

0

8

15

156

0

0

6

15

a - Times listed are .the hours after inoculation 'tiith an overnight broth culture of
Ps. aeruginosa .
b - Each of fifteen animals received four full thickness burns.
c - A positive culture was considered to be one in which five or more Ps. aeruginosa
colonies were isolated and identified from a burn .
d - Treatment consisted of 8.5% Mafeni~e Ointment or Dry Foam, applied to the
involved site every twelve hours fpr 156 hours . In addition, one burn per
animal served as the uninf8ct ed untreat ed control and one burn per animal
served as the infected untreated cont~ol.
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Untreated Control
Uninfected Untreated Control
8. 5% Mafenide Dry Foam
8. 5% ?,lafenide Ointment

1

3
2
1
0

12

132
156
84
108
72
96
120
141
Hours A f te r Inoculating Burned Anim::o. ls
36

24

FIGURE 1.

60

48

NUMBER OF INFECTED GUINEA PJGS DURING THERl\PY
WITH ~lA FEN I DE
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obtained from each burn area every t\·lelve hours in order to
isolate

and identify the t est organism.

The r esults of

this study are list ed in Tables XIV and XV , and are illustrated in Figure 2.
After 72 hours of treatme nt, a crossover study wa s
employed to determine the effectiveness of th e medicated
formulations in the era dication of a n e stablished burn
infection .

Therapy vdtb si lver sulfadiazine ointment

\'W Und
e.:r~d

d.ry

foam \1/as instituted on thos e a r eas previously treated v.'ith
the nonmedicat ed ointment and dry foam c ontrol s , r e spectively.
This regime vms continued until 156 hours after t he init i a l
inoculation of the burn areas.

The r esult s of this stud;:{ are

listed in Tables XVI and XVII, and a r e illustrated in Fi gure

3.

TABLE XIV
Silver Sulfadiazine Therapy of Burned Guinea Pigs at 72 Hours
No. of Pseudomonas Colonies0- Afte; T;.e~tm~;tc With
A1.n1ma
• 1 rumo
N ' er a

Ag Sulfadiazine
Dry Foam

Ag Sulfadiazine
Ointment

1

od

2

0

+++

3

0

4

0

Dry Foam
Control

Ointment
Control

'

+++

+-'--1..

+++

0

+

+++

0

0

+

+++

5

0

0

++

+++

6

0

+

++

+++

7

' -!-

++

+++

+++

8

0

+-t-+

+

+++

9

0

0

++

+++

10

0

0

+++

+++

11

0

0

+~ ~ 1·

+++

12

0

0

-H ··!·

-f--'--1.
'

13

0

++

+++

+·

,..!..

' 'T"

.
Vi

'-.()

TABLE XIV (continued)
No . of Pseudomonas Coloniesb After Treatment 0 Vlith
Ag Sulfadiazine
Ointment

Dry Foam
Control

Ointment
Control

Animal Numbera

Ag Sulfadiazine
Dry Foam

14

0

+++

++

+++

15

0

++

+++

+++

15

15

Total
:t-p

<

1*

0.05

>

I

7*

0 . 01

a - Each of fifteen animal s received four full thickness burns and were inoculated
with an overni ght broth cul ture of Ps. aeruginosa.
b - Cultures of each burn were obtained every 12 hours for 72 hours with sterile
swabs moistened with sterile water. Plating and incubating of the cultures
were followed by isolation and identification of the bact eria .
c - Treatment consisted of 2% Silver Sulfadiazine Ointment, 29.6 Silver Sulfadiazine
Dry Foam, Neobase Ointment Control, or Dry Foam Control appli ed to the involved
site every tr,velve hours for 72 hours.
d - Code :

0 = 0-4 colonies; + = 5-10 colonies; ++ = 11-20 colonies; +++ = 21 or
more colonies; iso1nt;cc1 and identified. from each burn as Ps .. a8ruginosa .

0':
0

TABLE "XV
Results of Silver Sulfadiazine Therapy of Burned Guinea Pigs
Numb er of Animals 0 With Positive
Pseudomonas Cult uresc After Treatmentd With

.J.lmea

m·

(hr)

Ag Sul fadi azine
Dry Foam

12

14

13

15

15

24

8

10

15

15

36

1

9

14

15

48

1

6

15

15

60

1

7

15

15

72

1*

7*

15

15

*P

< 0.05

I

I
I
I

Ag Sul fadiaz i ne
Ointment

Dry Foam
Contr ol

Ointment
Control

) 0.01

a - Times listed are the hours after inoculation with an overnight broth culture of
Ps . a eruginosa .
b - Each of fift een animals roc0-i.ved four full t hiclm ess burns.
c - A positive culture was co'il n :i.<1cJ.'cd. to be one in '\vhich five or more Ps . a eruginosa
colonies were isolated an d identifi ed fr·om a burn.

m

d - Treatment consisted of 2% Silver Sulfadiazine Ointment, 2% Silver Sulfadiazine
Dr y Foam, Neobase Ointment Control, or Dry Foam Cont rol appl ied to the involved
site ever y t\velve hours f or 72 hours ..
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FIGURE 2.

NlThlBER OF INFECTED GUINEA PIGS DU11ING
THERAPY WJTJ-I SILVER SULFADIAZINE

T!ABLE XVI
Crossover Silver Sulfadiazine Thbrapy of Burned Guinea Pigs at 156 Hours
No . of Pbeudo~onas Coloniesb After Treatmentc With
Animal Numbera

Dry Foam/Ag Se 1fadiazine

Ointment/~g

Sulfadiazine

Dry F,oam

OJ.ntment

1

odl

0

2

0

0

3

0

0

4

0

0

5

0

0

6

0

+++

7

+++

+++

8

0

0

9

0

0

10

+++

0

11

++ -1-

0

12

0

+-I-

13

0

0

()I
\_,'-)

TABLE XVI (continued)

No . of Pseudomonas Coloniesb After Treatmentc With
Ointment/Ag Sulfadiazine
Ointment

Animal Numbera

Dry Foam/Ag Sulfadiazine
Dry Foam

14

+++

+++

15

0

+ ++

4>!<

Total

5*

*P = 0.1

a - Each of fifte en animals received four full thickness burns and were inoculated
with an overnight; cult ure of Ps. a?ruginosa.
b - Cultures of each burn 'ttlere obtained every t welve hours for 156 hours with sterile
swabs moistened with sterile water. Plating and incubating of the cultures were
follo.,.Jed by isolation and identification of Ps .. aeruginosa.
c - Treatment consisted of the appli cation of Dry Foam or Ointment Controls to the
involved sites every t welve hours for 72 hours . This \•las followed. by application
of 2% Silver Sulfadiazine Ointment or 2% Silver Sulfadiazine Dry Foam every
twelve hours for 72 hours.
d - Code :

0
+
++
+++

= 0-4 Colonies if:iole:l:od and identified from each burn
= 5-10 Colon:lcn ieolatcd -and identified from each ~urn
=

11- 20 Coloni n.a l.oolo.teo. :J.nd identified f r om each burn

= 21

or more colonie n ioolnted and identified from each burn.

-

a-.

...-

TJABLE XVII
Results of Crossover Silver Sultadiazine Therapy of Burned Guinea Pigs
I J.me a

m·

I Number of Animalsb With Positi ve
Pseuaomonas Culturesc After Treatmentd 1ilith

Dry Foam/Ag Sul fadiazine
Dry Fbam

Ointment/Ag Sulfadiazine
Ointment

12

15

15

24

15

15

36

14

15

48

15

15

60

15

15

72

15

15

84

13

15

96

10

12

108

7

11

120

8

8

132

6

7

[br)~--

m

V1

TABLE XVII (continued)
:.n me a

m.

(hr)~-~

Number of Animalsb Wi th Positived
Pseudomonas Culturesc After Treatment With
Dry Foam/Ag Sulfadiazine
Dry Foam

Ointment/Ag Sulfadiazine
Ointment

lLJ-4.

4

5

156

4*

5*

*P = 0.1

a - Times listed are the hours after inoculat ion with an overnight broth culture of
Ps. aeruginosa .
b - Each of fifteen animals received four full t hickness burns.
c - A positive culture 1tJaS considered to b e one in \·Jhich five or more Ps. aeruginosa
colonies \-.rer e isolated and identified from a burn.
d - Treatment consisted of Dry Foam Control or Neoba se Ointment Control applied to
the involved s ites every b·mlve hours for 72 hours.. This therapy vras f ollm•Ied
by the application of 2% Silver Sulfadiazine Dry Foam or 2% Silver Sulfadiazine
Ointment to the involved sites every twelve hours for 72 hours.
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N1J!,mER OF INFECTED GUINEA PIGS DUR lNG CROSSOVER
THERAPY WJ TH SILVER SULFADIAZINE

DISCUSSION
In treating the massively burned patient, the physician
has available several alt erna tives 1-vith re spect to local
therapye

Fre quently, medicated ointments a re selected as

the vehicle for appiication of thera peutic a gent s useful in
preventing and treating microbial proliferation..

Alt houe;h

treatment based upon the application of medica t ed semisolids has proven to be an effective therapeutic approach,
one must be concerned with patient comfort during appl icat ion.
Ointments must be manually spread onto the involved sites
resulting in a painful experience for the patient.

The pos si-·

ble pain upon application may lead to a lack of patient
acceptance of this therapeutic technique, i n addit i on to complicating the already stressful situation.

li'urther, removal

of ointments to facilitate visual examinat i on of t he :.es:!.ons
is difficult due to the limited water solubility of most
components of this dosage form.
A second approach to local therapy includes the use of

various types of dressings ..

Occlusive dressings provide

both absorptive and protective functions upon application
to burns.

In addition, occlusive gauze dressings impregnated

\vith medicated s emisolids '\.vill provide a suitable therapeutic
effect.

HO\vever, optimal drainage from the burn must occur

in order to prevent maceration of the adva ncing edge of
ep:i.thelial grov1th.

If proper drainage does not occur, the
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increas e in maceration may r esult in a higher incidence of
infection and a a.ecrease in tis sue regeneration.

Further,

gauze dressings adhere to the v10und and produce pain and
tissue loss upon removal.
In addition t o the use of dressings containing semisol ids , gauze dressings medicated with 0.5% s ilver nitrate
can be select ed as

<;ill

alternate local therapeutic measuT-e .

This method requires the application of the solution e\-ery
t\·:o

hours in order to i nsure adequate solution levels

skin.

0 :1

the

The need to keep dressings saturated with the medicat ed

solution Hill r esult in increased nursing time per pati ent ,
and, therefore, has been considered to be a disadvantage,
along

\~Jith

the other dise.dvantages of staining , v.r etness and

coldness, and body el ectrolyte effects , previously described.
Due to the potential disadvantages associated Hi t h t he
current practices of local therapy for

~he

severely -burned

patient, an improved method of loca l treatment v1as dev i sed.
I n order to eliminate the n eed t o spread a

medicate ~

2¥; li-

cation manually onto the . burn, a nd to overcome the proslems
associated with the removal of medicated applications, a
hydrophilic foam \vas

formul ~ted.

Traditionally, a pre s-

surized aerosol is used t o generate a medicated foam at the
time of application.

However, an aerosol i'ormulation v1as

not sel ect ed for this vTOrk due t o the potentially harmful
effect that may be associated with the applicat ion of propellants, s olvents , and other similar aerosol auxi liary agents
t o denuded areas.

Rather, the hydrophilic foam was generated

(0

by whippinr; and casting an a erated film, dri ed to a uniform
moist ure content of 10%.

Once dried, the dry .foam appearerl.

as a light, flexible, aerated film.

Because of the r apid

water solubility of the components of the formulation,
application and subsequent liquefaction may be easily accomplished merely by placing the dry foam onto appropriate moist
surfaces. It \!las determined that 2. 5 em .. 2 of the dry foam
liquefies in 0.1 ml. of water at ambient temperature in 20
seconds.

In order to facilitate liquefaction, a fine 3ist

of "mter '\'as directed onto the burn lesions prior to each
application.
cal use.

A similar technique can be indicated in clini-

However, future clinical studies may demonstrate

that application immediat ely after soaking a patient :Ln the
Hubbard tank could provide sufficient moisture to insure
liquefaction, or inherent surface moisture present on th e
lesi ons may prove to be adequate for liquefaction .
Stability
Preliminary stability studies \'Jere performed in c::·d.er
to evaluate the dry foam on the basis of tackiness, flex:. bility, and general appearance after storage at various
tempera.tureso

In conjunction \llith this, the effect of var;/-

ing levels of humidity during storage was dBtermined (see
Tables IX and X).
Initial design of studies t o determine the effect of
temperature and humidity upon mafenide and silver sulfadiazine
dry foams utilized ointment jars as tight, light-resistant
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containers.

Samples were stored a t -5 0 , 50 , .25 0 , and 45 0 •

However, as liquefaction occurred with'ten of t he twelve
samples , it was assumed that a n ointment jar, although a
tight container, does not prevent passage of moisture.
Although the ointment j a rs did not provide the

pro~ec -

tion from moisture that vlas deemed essential for optimal
shelf life stability, several observations v.1ere made..

J.~iq_ue -

faction of the medicateQ. dry f oams storeo. in a saturat ed
environment was noted in l ess than 24 hours at a ll storage
temperatures.

It was observed that storage at 45° not only·

resulted in liquefaction but also a color change f or the
mafenide preparations.

It appeared that t he silver sulfa-

diazine dry foam could \A!ithstand the effects of temperGture
and humidity for longer periods of time the..1: could the mafenide
dry foam.
As liquefaction was noted· for all samples \vithln tv:o
months storage, it was assumed that an alternate
storage vms necessary.

me~~s

cf

For this reason, sealabl e, mois":Clre-

proof plastic bags were selected as protective containers for
the medicated dry foams.
mafenide and silver

In this second stability study ,

dry foams v7ere stored fo r
o
o·
o
o
four months in individual Ziploc Bags at -5 , 5 , 25 , 35 ,
sulfadi ~zine

and 45° in a dark environment.
After storage for four months, no change in appearance
''ms noted for the dry foams stored at 5°.
liquefied after four

v~eeks

storage .

Those stored at - 5°

Ho\·rever, the silver sulfa-

diazine stored at 25° retained its integrity throughout the

?2

study, v.1hi l e the mafenide dry foam stored at this temperature
liquefied within two months.

Storage in an oven at elevat ed

temperatures resulted in excessive moisture loss and loss of
flexibi lity.

With respect to the mafenide dry foam, a color

change "!as noted d.uring storage at elevated temperatures.
As a re sult of the data obtained from the stability
studies, several recommendations can be made.

The effect of

moisture is obvious, and therefore, future package design
should include the u se of plastics or other suitable materials
that are impervious to moisture.

It should be noted that the

plastic bags used in this study, although describ ed as "moistureproof, " do not prevent passage of moisture.

The

pre~; sure

seal,

or Ziploc, for these bags do not provide a completely tight
seal, and. therefore , do not serve as a totally \'Jater-impervious
container.
- -'rhe adverse effect of elevated temperatures upon-the
stability of the dry i:'oams Has noted in these studies..

Storage

of the ·formulati ons at 45°, resulted in a loss of pl~st~~ity
within one \'Jeek due to the evaporation of moisture from the
dry foam.

This sensitivity of the formulations to high tem--

peratures may nece ssitate storage o.t refrigerated conditions
in order to insure adequate shelf life.
In Vitro Re sults
In order to determine the effectiveness of the dry foam
as a dosage form, a modified agar diffusion test was performed
utilizing Ps. aeruginosa as the test organism.

Mafenide,
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silver sulfadiazine, si lver nitrate, gent a micin, a nd
nit rofurazone \:Jere sel ected as typical topical antibacterials
for study since t hese agent s are frequently indicated in
l ocal burn therapy.

The diameters of the zones of inhibition

observed vdth the medicated dry f oam formulations V·Tere compared with those of the corresponding medicat ed ointments
( see Table VIII).
Hafeni de , 8 .. 5%, was tested in vitro as the dry f oa::-:1 and
also as the commercially available ointment.

The mea n dia-

meter for 15 replicate determinat ions u sing mafenide <iry f oam
mea sur ed 27 .. 2 mm., \•Jbile s imi l ar testing of the ointment fo:rmulations produced zones equal t o 25.9 mrn..

In spite of the fact

that the dry foam produced. larger zones, student t eYaluation
of these results suggest t hat a significant dif ference may
not exist "between the mean diameters of the zones of inhi bi t-ion (P < 0.1 > 0.05).

For this reason, iv was assumed that

the dry foam \vas as effective as the ointment \>Jhe:1 testing
in vitro release of mafenide from these two dosage

f cr~s .

Due to the r ecent i nt er est in silver sulfadiazine in
local burn therapy, in vitro tests \'Jere performed even though
this agent has not r eceived _final Food and Drug Administration
approval.

Hi th no ·product of silver sulfadiazi ne commerci ally·

avail able, Neobase Ointment \llas selected a s t he ointment
v ehicle to \•Jhich 1, 2, and 3% silver sulfadiazine \•Tas added.
In addition, dry foam formulations
these conc entrations .

\I/

er e prepared containing

Zones of inhibition measured 17.1 mmo

fo r 1% silver sulfadi azine dry foam and 8 .. 5 mm .. for the

4

corresponding ointment (P

< 0.001).

In testing the 296

ointment, the zones measured 9. 7 mm. , \l!hj_le the dry foam
at this concentration produced zones of 16.6 mm . (P

< 0 .. 001) .

For the 3% concentration, the zones measured 9.'7 mm. and
20.6 mm., respectively (P ( 0.001).

Significance,. as dete:r.··

mined by student t evaluati on, indicated that the zones of
inhibition, and hence, release of the therapeutic agent, were
greater for the medicated dry foam than for the cor re spcndi ::1g
medicat ed ointment.
Clinically, silver nitrate is applied topically as a
dressing saturated v.dth 0 . 5% silver nitrate solution .

now-

·ever, fo r this study, 0.5% silver nitrate in Neobase Oir.tment~
and also in the dry foam vJere prepared and evaluated in _v i t£.2. ..
Mean diameters of the zones of inhibition measured 12.8 mm .
and 9.3 mm . for the dry f oam and ointment preparat ions ,
respectively.

As was the case vrith silver

sulfadiazi~

the dry foam proved to b e a bett er dosage f'orm tbc-...n t he
corresponding ointment , as determined. b;y the subseque::t student
t evaluation (P ( 0.001).
In determining the in vitro effect iveness of- the dry foam
and ointment as a vehicle for 0.1% gentamicin, liquefaction
of the ointment occurred during incubation.

Due to the lique-

faction and resultant flov.Ting of the ointment onto the seeded
agar plates, it is possible that exagger ated fa l se values
wer e obtained.

In spite of this possibility, zones were

measured and evaluated.

1-i'or the medicated dry foam, mean

values of 12.3 mm . were r ecorded , while values for the medica ted
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ointment measured 13.6 mm.

Student t computations suggest

no signi fi cance between the means of the data obtained
(P

< 0.1

) 0.05) .

li'or this reason, it was assumed t hat t he

dry foam and ointment v1ere equally effect i ve as dosage forms
for gentamicin.
Nitrofurazone has been fr equently u sed to treat various
infected l esi ons of the skin. The topica l vehicl e for nitro.
a
furazone , Solubase, has been described as a vJater solutle
dressing for use on infect ed burn lesions.

Therefore , in

orde r to compare this water solubl e drug product \vith t he
dry foam, nitrofurazone \·Jas included in the in vit.E.Q_ studies .
Hm.,rever, no zones of inhibition '!!Jere detected with either the
0.2% dry foam or ointment.

Because of this, it v;as assumed

that nitrof uraz one i s not effective against t he str ain of
Ps..!.. aeruginosa used in this study.
-Based upon the in

v~tro

agar diffusion studies, the

relative effectiveness of the dry foam and ointment
forms VJas ascertained.

dosa~e

The data indicated that r elease =·ates ,

as determined by the zones of inhibition, from the dry foam
v1er e at l east as gr eat as that from the ointment s .

In the

ca s e of the silver salts , the dry foam preparations produced
statistically l ar ger zones of inhibition than the correspond-ing ointment prepa r ations.

On the other ha nd, mafenide a nd

gentamicin containing dosage f orms produced equivalent zones
of inhibition and, henc e , equiva lent r a t es of release.

a - Ava ila ble from Eaton Laboratories, Division of the Norv1ich
Pharmaca l Co .. , Norwich, N. Y.
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In orde r to further evaluate the dry fo a m as a. dosage
form, mafenide v-Ias subsequently sub,jected to in vivo t estinr.; ..
f1afenide was selected for the in vivo studies because the
in vitro data showed. that this therapeutic agent vms the mos t
effective in vitro inhibitor of Ps. aeruginosa.

-

----- -

Further, a s

release rat e s from the dry foam and ointment vJere statistica lly
equivalent, in vivo testing was deemed necessary in order to
further substantiate this conclusiono
Silver sulfadiazine was also selected for in v1vo t esting.

The silver salts in the dry foam produced significently

greater zones of inhibition than in the corresponding

oint ment~

Therefore, in vivo testing of silv-er sulfadia zine was

indi~·

cated in order to further determine if the d.ry .foam \._rould.
serve as a topical dosage form of choice for t his silver s alt ..
In Vi vo Results
V/ith initial surface growth of Ps.

aeruginos~

primary concern in burn vJound sepsis, the burned,

beir!g of

in ~"ec-'::e o.

guinea pig was selected as the model for comparing the

e ~fe c

tiveness of medicated dry foams \•lith corresponding ointments .
As supra-eschar bacterial colonization is usually considered
to be the first stage of local sepsis, it \!las believed that
eradication of surface colonies would indicate the effectiveness of the medicat ed dosage form.

Therefore, a negative s wab

culture was selected as the parameter of effectiveness for the
medicated preparations.
It must be noted tha t other investigator s have utilized
mortality as an indication of the effectiveness of a particula r

7'7
local t herapeutic regime.

Hov;ever, as mentioned earli ei',

variables, such as virul ence of the test organism a nd the
traumatic effect of the thermal injury, may adversely affect
the mortality rates.

Furthe r, tests utilizing mortality rates

necessitat e long periods of study which may introduc e a
variable.

thi ~·d

Specifically, the eschar, onc e f ormed , can lead. to

constriction and inhibition of r espiration l eading to possibl e
death of the animal.

For this reason, long term studie s may

require the us e of surgical procedures such as debriderr.ent
and eschar removal as part of loca l supportive care..

I n order

to avoid the need to develop suitable surgical techniques,
and also to avoid the problems of virulence and trauma ,

m er~

tality r ates v.fere not used as indicat ors of effectiveness .
Rather, the a bsence of the test organi sm on the surface of
the . burn \>Jas determined in order to compare the effectiven•: ss
of the dry foam \'Tith the corresponding ointment.
The in vivo efficacy of the dry foam as a dosage
was determined utilizing 8. 5% mafenide.

fc~m

Once sui tabl e barn-·

ing techniques \vere developed, it was possible to inflict four
full thiclmess injuries of uniform size onto the dorsum of
each animal.

In this manner, the two medicat ed dosage f orms

could be evaluated on each animal.

Further, the effect of

diffusion from one area to another was determined by util i zing one burn as the infect ed, untreated control.

The in vitr o

tests produced very large zones of inhibition, a nd it vias
assumed that if diffusion from a medicat ed a r ea was to oceur,
the untreat ed infected area ,,.,ould not demonstrate the presenc e
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of Ps. aeruginosa.

However , the untreated infected areas

gave pos itive cultures for the test organism throughout the
study.

For this r eason , it was as sumed that diffusion of

the active ingredient from one a r ea to another did not oc cur,
and ther efore, did not ha ve an inhibitory effect upon the t est
organism .

Therefore , the use of f our burn areas per animal,

each treated v.Jith a different dosage form, appear ed to be a
reasonabl e method of study.
In order to determin e i f cross contamination might occur
from a n infected burn to an adjacent area of no coloniz2.tion,
the fourth burn pe r animal \vas not seeded.

Th.i s burned, unin-

fected, untreated a r ea served to demonstrate that recol oni zation \<Ja s occurring throughout the study since s ix animals gave
posit ive cultures at the conclusion of the study .

From this

observation, i t was a ssumed that cross contanination of tho
other burn areas vJas occurring at a simila r rate .

HO\\'ever ,

as the burn a r eas treated \<lith the medicated dry foam

a.r.~.d.

the

medicated ointment produced no positive cultures , it is suggested that both dosage forms vmre equally effective in inhibiting the grovrth of Pseudomonas in vivo.

That is , both prepara-

tions er adicated s upra - eschar colonization after 36 hours of
therapy and subsequently prevent ed the cross cont amination
that was expected to occur due to the presence of Pseudomonas
on the ot her burn areas .

It should be not ed that both the

in vitro a nd in vivo methods of study suggest that the dry
foam a nd the ointment are equally effective dosage forms for
mafenide (see Tables VI and XIII ).
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In an attempt to demonstrate t he presence of Ps .
aeruginosa on the burns visually, the method of \!lard (48)
and Caplan (52)

'~:Jas

used.

Ultraviolet light vms directed

onto the burns to detect the cha ract eri stic .fluoresc enc e of
Pseudomonas.

Unfortunately , mafenide fluoresced with a simi-

lar intensity and color to that of fluorescein, a nd,

tbere ~·

fore, no differentiation could be made between t h e presence
of Pseudomonas and the presence of mafenide.

Ho~o1ever,

the

untreated, infected areas produc ed fluoresc ence characteristic

of Ps. aeruginosa.

Of the fifteen infect ed , untreat ed

burns, all produced fluor escenc e on exposure to ultraviolet
'light.

This indirect visual demonstration of the presence

of test organism tends to substantiate the swabbing techni que
used, f or a ll infected , untreated burns produc ed positive
cultures for Pseudomonas.
In addition, macroscopic examination of the burned-,uninfect ed areas under ultraviolet light prod.uced fluorescence
\•lith five of the animals.

In contrast to this , six of t hes e

areas produced cultures positive for Pseudomonas.
cre_p ancy

betv~een

The dis-

the number of fluore s cent areas and the

numbe r of areas with positi'!"e cultures may be explained by
the limitation of t he ultraviolet technique.

According to

Polk et a l (53), fluoresc ence of Pseudomonas may b e observed
the naked eye as the concentration approa ches and exceeds
105 organisms per cm2 .. Evidently , the proliferation of
~olith

Pseudomonas was not of s ufficient magnitude and henc e , the
fluor escence vms not visibl e on the sixth area .
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Once the i n vivo . test ing of mafenide dry foa m and oi nt ment
substantiat ed the in vi tro data previously obtained , in vivo
evaluation of 2% silver sulfadiazine dry foam a nd in Neobase
Ointment was initiated in order to furthe r determine t he
advi sability of using the dry foam as a topical dosage form
in infect ed burns.

In this second study, each of fift een

guinea pigs were inflicted ,.Jit h four ther ma l injuries .

Hmv-

ever , unlike the mafenide study, all four areas vJere chall enged
with an overnight broth culture of Ps. aer uginosa, and ea ch
burn v1as a ssigned a particular t herapeutic r egime .

Thera py

consisted of 2% silver sulfadiazine dry f oam , 2% silver sulfa diazine in Neobase Ointment , dry foam control, and Neobase
Ointment control, appl ied t o the involved sit es every twe lve
hours f or 72 hours.

Svm b

cultures Her e obtained. ever-:f tvlel ve

hours , and isolation and identification of t he t est organ i sm
\vas a ccomplished (see Table XV).
After 72 hours of treatment, all of the unmedicateo c ontrol a r eas continued to demonstrate the presence of ths ·oac-teria..

Of the fifteen animal burns treated wit h 2% silver

sulfadiazine dry foam , one remained infect ed with Pseudomonas ..
In contrast to this , seven of the fifteen animal burns r emained
positive for Pseudomonas after treatment v1i th the corresponding medicated ointment .

Visual examination of the burns upon

exposure to ultraviol et l ight produced .fluorescence ,., ith a ll
burns treated \vith the unmedicated d.osage forms ..

The burns

treated \·Jith 2% si lver s ulfadiazin e dry foam failed to sho'v
fluorescence, while two of the fifteen ani mal burns t r eat ed
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i-Jith the medicated ointment produced fluor e scence .

The

discrepancy bet\'.Teen the fluorescent identification and the
s\..,rab culture identification Has attributed to the concentration limitation of the ultraviolet technique, previously
described.
After 72 hours of treatment, a crossover study N'as
initiated utilizing the burn areas previously treated with
the unmedicatea. dosage forms (see Table XVII) .

Those areas

treated \d.th the unmedicated dry foam \v ere assigned the!'a py
with the silver sulfadiazine dry foam , applied every tvJelve
hours for 72 hours.

In a similar manner, those areas pre-

viously treated ,.lith Neooase Ointment were assigned a treatment regimen utilizing silver s ulfadiazine in Neobase Oi r..tment.
In this way, the effect of instituting therapy one-half hour
after infecting the burns could be compared v.'ith the data
obtained from the study instituting therapy 72 hours after
infecting the burns.

In addition, determining

e.ffic ac:~

utilizing crossover methods may be of value i n negatir-s
inherent variables of the in vivo study.
At the conclusion of the in vivo crossover study, f our
of the animal burns treated \<rith the medicated dry foam
remained infected, \<Jhile five of the areas treated \·' lith the
medicated ointment r emain ed infected.

No significance could

be assigned to the data, as determined by Chi Square computations (P

= 0 .. 1).

Vlith regard to the init ial study of the

silver s ulfadiazi n e dosage forms, however, significa nce may
exist (P ( 0.05

> 0 . 01).
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Several factors must be considered in comparing the
results of the initial in vivo study of the silver sulfadiazine dosage forms vTith that of the subsequent crossover
study.

The 72 hour delay in instituting appropriate th er apy

may have led to antiba cterial activity not s eriously aff ect ed
by rates of release from the dosage form.

The proliferat ion

of the test organism during this initial 72 hour period probably result ed in sub-eschar colonization.

This

movemen~

of

Ps. aeruginosa into tissues bel0\-7 the burn produced an envi ronment for gro\lrth not easily treated with locally applied agents.
In clinical use, local and syst ernie thera py v.rould be ind:i.cat ed
in order to successfully combat the advanci ng bacteria.

In

addition, surgical excisi on of the devita l ized eschar v;ould
be a n abs olut e necessity in order to aid in th e elimination
of the infecting organis ms .

The presence of es char provid•3S

an -excellent medium for bacterial growth and also provide s a
barrier between the applied drug and the sub-escha r c olcnie s,
which prevents therapeutic contact a nd eff ect.

Therefor e ,

·the omission of systemic therapy and eschar removal from"t he
cross over study may have led to the l ack of significance in
the data.
Therefore, from the in vivo study utilizing the s ilver
sulfadiazine dosage forms, two s ets of dat a \•Jere obtained.
First, v..rith therapy initiat ed one-ha lf hour after inoculat i ng
the burns, the medicated dry foam result ed in a decreased
incidence of infection to l ess tha n 10%.

Loca l t her a py with

the corresponding medicated ointment r educ ed the numbe r of
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inf ected animal burns from fift een t o seven, or 46%..

This

differenc e may be due t o the rapid release of silver s ulfa -·
diazine from the foam with s ub s equent rapid therapeutic effect.
Comparing these data with the res ults of the in vitr o determinations, it appears tha t the dry f oam containing the si lver sal ts
is a better dosage form tha n the corresponding medicat ed ointment.
'rhe second s et of data to be cons idered \!Jer e those obtain ed
using animals infected for 72 hours \·.r ithout appropriate ther apy .
As no significant difference vms not ed in thos e anima ls treated
\:J i th the medicated dosage forms, one may conclude that t he dry
fo am i s at least as effective as the ointment .
In evaluating the r esults of the in vit!:_'o and in vi v o
studies, several possible c orrel ations may be made .

If no

signi.fica:1t difference can be determined fror.1 t he in vi t:::-Cl data ,
then the incidence of infection in vivo ma y be the s ame for both
dosage forms.

This occurred \·Ji th the mafenide studies .

If ,

on the other hand, zones of inhibiti on \·Jere significant:l.;ygreater, then the incidence of infection in vivo may also be
greate r.

This assumption was demonstrated in the silv er

sulfadiazine studies.

However, the effect of delaying t he r apy

in vivo may be to counteract the r apid release and r apid effect
expected.

This was demonstrated in the crossover silver s ulfa-

diazine study as equivalent incidence of infection was n oted
regardless of dosage .form used .

SU~1MARY

AND CONCLUSIONS

The purpose of thi s study v.Jas to formulate a topical
dosage form v!i th characteristics that permit appl ication. -:;o
denuded a r eas , s uch as a burn, vlithout inunction.

Selection

of components for the formulation v1as based u pon l ack of
toxi city a nd accepted u se in human

subjects~

I n addition ,

properties such as r a pid t:Jater solubility, f l ex i b i lity , e a se
of adherence, and ease of remova l from both denuded. and intact
areas of the skin were considered to be prime r equisites for
the dosage form.

Of s pecial import a nc e \•.ras the ability of

the formulation to demonstrate not l ess tha n equiva l ent
efficacy when compa red to ointment bases i n current u s a ge .
In order to develop a dosage form with these chare.ct eris-··
tics , a topical v ehi cle in the f orm of a dry f oam was
l at e d.

fo~ffiu

A hydrophilic, aerated film was compounded one:_ e-v-aluated

by the u se of in vitro and in v ivo methods.

In addition, p r e-

liminary stability tests \•Jere performed to ins ure adecuat e
shelf life.
The rel ease of therapeutic a gents i n vitr o from dry f oam
formulations 1<1as compared

~t.Jith

that of correspondi ng ointment

bases , utilizing a modified agar diffusi on t est .

Th ese s hov1ed

t ha t s ilver nitrate a nd silver s ulfadiazine produced significantly l arger zon e s of inhibition \•Jhen used as the dry foam
rather t han as an ointment.

Hov.rever , mafenide and gentamicin
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produced equivalent release rates from both the dry fo am an.d
ointment formulations .
In vivo studies demonstrated that incidence of infection
using the burned, infected guinea pig Has statistically equivalent v1hen mafenide vms applied as either the dry foam or t he
commercially available ointm ent.

A therapeutic regime using

silver sulfadiazine dry foam produced significantly bett er
results than with the corresponding ointment if therapy

v.'2.S

initiated one-half hour after inoculating the animal burns.
However, by delaying therapy for 72 hours, incidence of infection after treatment Nith either preparation was \·.rithout significant difference.
As a result of the in vitro and in vivo studies, it
appears that a medicated dry foam will be value as a v ehicle
for topical use.

By eliminating the need to spread the dosage

form onto skin lesions manually, the dry foam may prove to be
of value in treating the seriously burned patient.

Fir..ally t

by the use of a highly water soluble topical dosage f crc,
ease of removal may be of benefit to those involved v1ith the
burn patient .

The encouraging data obtained in this work,

indicates that the therapeutic concept of a medicated dry foam
has great potential, and should be subjected to clinical
investigation at the earliest opportunity.
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